News
-
Scientists Just Found an Unexpected Link Between Tuberculosis and Parkinson’s Disease
(May 29, 2018) – A new study has found an important link between tuberculosis and Parkinson’s disease. This connection is a protein called leucine-rich repeat kinase 2 (LRRK2), and not only could it help develop new treatments for both diseases, but it …
-
Phase 1 Trial Finds Potential Parkinson’s Vaccine, Affitope PD01A, to be Safe and Possibly Effective
(May 29, 2018) – Affiris’ experimental Parkinson’s vaccine, Affitope PD01A, is safe and effectively triggers an immune response against the alpha-synuclein (aSyn) protein, data from a series of four consecutive clinical trials show. Read more…
-
FDA Continues Crack Down on Unapproved Stem Cell Clinics
(May 10, 2018) – The US Food and Drug Administration (FDA) is seeking permanent injunctions to stop two US stem cell clinics from marketing stem cell products without the agency’s approval and for “significant deviations” from current good manufacturin …
-
Introducing Little Big Things™ from Sunovion Pharmaceuticals Inc.
(May 9, 2018) – We know that all ideas—big and small—may improve the experience of someone living with Parkinson’s. Innovation happens outside the research lab all the time, all around us, by all types of innovative thinkers. Unique ideas may come from …
-
Researchers Find That Lipid Accumulation in the Brain may be an Early Sign of Parkinson’s Disease
(April 29, 2018) – A collaborative team of researchers at McLean Hospital, a Harvard Medical School affiliate, and Oxford University has found that elevated levels of certain types of lipids (fat molecules) in the brain may be an early sign of Parkinso …
-
Experts Weigh the Benefits of New Parkinson’s Drugs
(April 25, 2018) – Levodopa, is the gold-standard medicine for Parkinson’s disease but nothing is available that can slow or reverse the loss of brain cells, and what’s more, levodopa’s effects wane over time. So-called “off” episodes, when the drug is …
-
Targeting New Compound Slows Parkinson’s Disease in Rats
(April 22, 2018) – New research finds that acrolein, a byproduct of oxidative stress, is key in the progression of Parkinson’s disease. Targeting the compound was found to slow down the condition in rats — a discovery that may soon lead to new drugs fo …
-
Two Markers of Parkinson’s Progression May Help Trials in Newly Diagnosed Patients
(April 11, 2018) – A recent study in in the journal Movement Disorders reports that clinical trials in patients with early stage Parkinson’s may benefit from assessing markers of disease progression — namely, changes in the Movement Disorder Society (M …
-
Adamas Announces Multiple Data Presentations at the American Academy of Neurology Annual Meeting
(April 12, 2018) – Adamas Pharmaceuticals, Inc. announced it will make six data presentations at the 70th Annual Meeting of the American Academy of Neurology (AAN) on April 21-27, 2018 in Los Angeles, California. Read more…
-
Educational Program on Medical Marijuana and Other Emerging Therapies in the Treatment of PD
(March 30, 2018) – Please join Dr. Jill Farmer on Friday, April 27, 2018 for a free educational program on Medical Marijuana and Other Emerging Therapies and Their Role in PD. The program is sponsored by Drexel Neuroscience Institute and will be held a …